Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CRS Clear all
Withdrawn Phase 2 Interventional

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

NCT01095523
View directory record Official record
Conditions
Colorectal Carcinoma, Peritoneal Carcinomatosis
Interventions
Laparotomy+ HIPEC +/- CRS
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 6:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Neurodevelopmental Outcomes in Craniosynostosis Repair

NCT04072783
View directory record Official record
Conditions
Craniosynostoses
Interventions
MRI,DTI, functional MRI
Diagnostic Test
Lead sponsor
University of Arkansas
Other
Eligibility
Up to 4 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 6:22 AM EDT
Active, not recruiting Early Phase 1 Interventional

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

NCT04514029
View directory record Official record
Conditions
Lymphoma
Interventions
Simvastatin, Dexamethasone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332
View directory record Official record
Conditions
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Interventions
dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 22, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

NCT02872714
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
34
States / cities
Tucson, Arizona • San Diego, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 6:22 AM EDT
Active, not recruiting Phase 2 Interventional

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

NCT01815359
View directory record Official record
Conditions
Appendix Cancer, Colorectal Cancer
Interventions
Cytoreductive Surgery, HIPEC with Mitomycin-C, EPIC with FUDR and Leucovorin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 6:22 AM EDT
Not listed No phase listed Observational

ERAS® Guidelines Validation of CRS With or Without HIPEC

NCT05185791
View directory record Official record
Conditions
Peritoneal Diseases
Interventions
Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
Other
Lead sponsor
Hospices Civils de Lyon
Other
Eligibility
18 Years and older
Enrollment
288 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 22, 2026, 6:22 AM EDT
Not listed No phase listed Observational

Endotypic Stability in CRS

NCT06272123
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
no intervention
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Jul 22, 2026, 6:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

NCT04604132
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 22, 2026, 6:22 AM EDT
Not yet recruiting Not applicable Interventional

Active vs. Passive VR During Office-based ENT Procedures

NCT07599826
View directory record Official record
Conditions
Pain, Anxiety, Chronic Rhinosinusitis (CRS), Nasal Obstruction, Nasal Polyp, Eustachian Tube Dysfunction, Dysphonia, Subglottic Stenosis (SGS)
Interventions
Virtual reality headset or goggles
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 6:22 AM EDT
Recruiting Not applicable Interventional

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

NCT07290140
View directory record Official record
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
Airiver ESSpand DCB, ESS
Combination Product · Procedure
Lead sponsor
Airiver Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 6:22 AM EDT
Completed No phase listed Observational

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913
View directory record Official record
Conditions
Urothelial Cancer, Receptors, Fibroblast Growth Factor
Interventions
Archival Tumor Tissue Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 22, 2026, 6:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

NCT07299474
View directory record Official record
Conditions
Inferior Turbinate Hypertrophy, Chronic Rhinosinusitis (CRS), Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

NCT04003610
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 22, 2026, 6:22 AM EDT
Terminated Phase 4 Interventional Results available

Tranexamic Acid for Craniofacial Surgery

NCT00722436
View directory record Official record
Conditions
Craniosynostosis, Bleeding
Interventions
Tranexamic acid, saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Jul 22, 2026, 6:22 AM EDT
Suspended Not applicable Interventional

Sinopsys Lacrimal Stent Study for Patients With Chronic Sinusitis or CRS

NCT03066908
View directory record Official record
Conditions
Chronic Sinus Infection
Interventions
Sinopsys® Lacrimal Stent
Device
Lead sponsor
Sinopsys Surgical
Industry
Eligibility
22 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Greeley, Colorado • Boca Raton, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Jul 22, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

NCT04045613
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 22, 2026, 6:22 AM EDT
Completed Phase 4 Interventional Results available

The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery

NCT02188576
View directory record Official record
Conditions
Craniosynostosis
Interventions
high dose TXA, Low dose TXA
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 6 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jul 22, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

NCT01703481
View directory record Official record
Conditions
Tumor or Lymphoma
Interventions
JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3, JNJ-42756493: Part 4
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 22, 2026, 6:22 AM EDT
Completed No phase listed Observational

Genetic Analysis of Craniofrontonasal Syndrome

NCT00339846
View directory record Official record
Conditions
Craniofrontonasal Syndrome, CFNS
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 6:22 AM EDT
Terminated No phase listed Observational

Comparison of Chitodex Gel Vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

NCT05083741
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Chitogel, Nexfoam
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 6:22 AM EDT
Withdrawn Phase 1 Interventional

Intraperitoneal LSTA1 in CRS-HIPEC

NCT06216561
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Carcinoma, Appendix Cancer, Peritoneal Metastases
Interventions
CRS-HIPEC + LSTA1, CRS-HIPEC alone
Drug · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 22, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

NCT05035654
View directory record Official record
Conditions
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Interventions
LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), Bilateral sham procedure control (Part 2)
Drug
Lead sponsor
Lyra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Carlsbad, California • La Mesa, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 22, 2026, 6:22 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy of Amicar for Children Having Craniofacial Surgery

NCT02229968
View directory record Official record
Conditions
Craniosynostosis
Interventions
Amicar (ε-aminocaproic acid), normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Months to 36 Months
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 6:22 AM EDT